A Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms BOSTON II
- 07 Jun 2017 Biomarkers information updated
- 04 Nov 2015 Planned primary completion date changed from 1 Feb 2018 to 1 Sep 2019 as reported by ClinicalTrials.gov record.
- 04 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.